|
1.2 BIOLOGIE - BIOBANQUES
| |
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
| |
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
| |
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
| |
|
|
5.10 TRAITEMENTS - ESSAIS
| |
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
| |
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
| |
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
| |
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
| |
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
| |
|
Bristol-Myers Squibb and Celgene [In the Pipeline]
| |
|
| |
|
Lisa Jarvis notes that there’s $2.5 billion of “synergy” in the deal – that is, stuff that will be cut – and 35% of that is listed under R&D. If there’s anyone at Celgene who’s wondering, wonder no more: the majority of those savings are surely going to be extracted from your organization. I cannot recall a pharma takeover where this has not been the case.
| |
| | |
|
|
|
In a Huge Biopharma Shakeup, Bristol-Myers to Buy Celgene For $74B [Xconomy]
| |
| | |
|
Celgene is known for its sprawling network of partnerships and alliances with smaller biotech companies that is arguably unprecedented in the life sciences sector. But massive biopharma acquisitions have a mixed track record, and the big splash often creates a ripple effect on the smaller biotechs that have signed deals with each of the larger companies.
| |
| | |
|
|
|
Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal [STAT]
| |
|
| |
|
The deal gives Bristol chief executive Giovanni Caforio a new topic of conversation and access to several cancer franchises, including experimental cell therapies that attack tumors, that will expand his company’s cancer footprint. But it also means he will have to deal with Celgene’s problems, including the potential Revlimid patent expiration.
| |
| | |
|
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
| |
|
|
5.5 ASCO
| |
|
|
6.6 PUBLICATIONS
| |
|
Poor Financials Pushes PLOS To Ponder Future Prospects [Scholarly Kitchen]
| |
| | |
|
Revenue at PLOS was down by nearly US $2 Million in 2017, largely the result of declines in submissions to PLOS ONE, its largest journal, according to the report. More importantly, PLOS wrote off US $11.1M in expenses in building Aperta — a manuscript submission system that the publisher ultimately decided to abandon after years of development.
| |
| | |
|
|
6.7 DMP, BIG DATA & APPLIS
| |
|
|
6.7.3 DMP
| |
|
Most U.S. patients not using online medical portals [Reuters]
| |
| | |
|
Among the reasons participants gave for not using online portals, 25 percent mentioned issues with internet access, 32 percent said they had no online medical record, 70 percent said they preferred to speak directly to the doctor, and 22 percent were concerned about privacy issues.
| |
| | |
|